Abstract
Objective: Performing a cost-utility analysis to assess the treatment with different insulin options in patients with Type 2 Diabetes. Methodology: Based on the analysis previously performed by Romero et al., we updated the information and included an specific analysis for the quality of life. The Markov model simulated patients treated with nph, determir, or glargine insulin. We considered the hypoglycemia events and their complications. The costs corresponded to the maximum regulated price per dose. The event costs were taken from the transaction information system records of health care providers in 2014. Results: The qaly with detemir are calculated as 2.604, compared to 2.545 with glargine, and 2.533 con nph. The sensitivity analysis show determir dominance. Conclusions: Detemir is a favorable option due to its safety, effectiveness, and cost, with proven benefits measured in qaly over the other items being compared.
Copyright notice
The Journal Management and Health Policies is registered under the Creative Commons Recognition 4.0 International license. Therefore, this work can be reproduced, distributed and publicly communicated in digital format, provided that the name of the authors and the Pontificia Universidad Javeriana are recognized. It is allowed to quote, adapt, transform, autoarchive, republish and create from the material, for any purpose (including commercial), provided that authorship is properly acknowledged, a link to the original work is provided and if changes have been mad. The Pontificia Universidad Javeriana does not retain the rights over published works and the contents are the exclusive responsibility of the authors, who preserve their moral, intellectual, privacy and publicity rights.
The endorsement of the intervention of the work (revision, style correction, translation, layout) and its subsequent disclosure is granted through a license to use and not through a transfer of rights, which means that the journal and the Pontificia Universidad Javeriana disclaims any liability that may arise from ethical misconduct on the part of the authors. As a result of the protection provided by the license for use, the journal is not obliged to publish retractions or modify the information already published, unless the erratum arises from the process of editorial management. The publication of contents in this magazine does not represent royalties for taxpayers.